An observational study in Obesity, Morbid, Bariatric Surgery and Intestinal Permeability, sponsored by Toros University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 19 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Toros University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Obesity, Morbid with a site in Turkey — 8 open to participants now, 8 under way, 1 of them phase 3. Obesity, Morbid · Turkey.
Among the 70 studies in Obesity, Morbid with a site in Turkey, this one is the 21st largest by planned enrollment of the 32 observational ones that give a count, is one of 5 that started in 2026, is one of 32 observational ones, and was the 65th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →8 of the 70 studies in Obesity, Morbid with a site in Turkey are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Turkey, Germany, Spain
Ages 2+
Kocaeli University · Sites in Turkey
Ages 18–80 · Men only
Harran University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Başakşehir Çam & Sakura City Hospital · Sites in Turkey
Ages 18–65
Gazi University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 19 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 80 across 311 observational studies indexed under Obesity, Morbid.
Median enrollment 66 across the 38 interventional studies, 68 across the 32 observational. Of the 52 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 70 have an industry lead sponsor. The 10 most frequent:
Toros University is the lead sponsor of 21 studies on the registry; 11 are open to participants now.
Toros University has 1 study filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity, Morbid with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220772Phase 3Regeneron PharmaceuticalsA Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults | 2027-06-18 |
| NCT07643376Toros UniversityEvaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management | 2027-01-01 |
| NCT07668765Gazi UniversityGLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity | 2027-04 |
| NCT05927519Kocaeli UniversityComparison of Airtraq in Class 2-3 Obese and Nonobese Men During Intubation: a Prospective Randomized Clinical Study | 2027-10-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 70 studies in Obesity, Morbid with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment.
Obesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success.
In this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed:
The study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.
Obesity is defined by the World Health Organization (WHO) as abnormal or excessive fat accumulation that presents a risk to health. Bariatric surgery, particularly Laparoscopic Sleeve Gastrectomy (LSG), is considered the most effective long-term treatment for morbid obesity.
This prospective observational study will be conducted at Bursa Yıldırım Doruk Hospital with 40 volunteers who have undergone LSG within the last month. Participants will be evaluated at baseline (immediately after surgery) and at 6 months post-surgery.
Assessments include:
Statistical analyses will be performed using the Statistical Package for the Social Sciences (SPSS) 22.0. Normal distribution will be assessed using Kolmogorov-Smirnov/Shapiro-Wilk tests. Results will be expressed as mean ± standard deviation for continuous variables and frequency/percentage for categorical variables.
Adults with morbid obesity who underwent Laparoscopic Sleeve Gastrectomy (LSG) at Bursa Yıldırım Doruk Hospital General Surgery Clinic within the last month, meeting the inclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 19-50 years who underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last month at Bursa Yıldırım Doruk Hospital. Participants will be evaluated at baseline and 6 months after surgery for metabolic parameters, intestinal permeability markers, gastrointestinal symptoms, anthropometric measurements, and dietary intake.
Other: Clinical and Biochemical Assessment
Participants will undergo two assessment visits: at baseline (within 1 month post-surgery) and at 6-month follow-up. Each visit includes anthropometric measurements (body weight, height, waist and hip circumference, BMI), biochemical blood analysis (fasting glucose, lipid profile, insulin, zonulin, secretory IgA, LPS), gastrointestinal symptom evaluation via GSRS, and 3-day dietary records.
Also known as: Anthropometric Measurement, Biochemical Blood Analysis, Gastrointestinal Symptom Rating Scale (GSRS), 3-Day Dietary Record, Intestinal Permeability Assessment
Change in Fasting Blood Glucose Concentration (mg/dL)
Change in serum fasting blood glucose levels after 12-hour fasting between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in Total Cholesterol Concentration (mg/dL)
Change in serum total cholesterol levels after 12-hour fasting between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in Triglyceride Concentration (mg/dL)
Change in serum triglyceride levels after 12-hour fasting between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in HDL Cholesterol Concentration (mg/dL)
Change in serum high-density lipoprotein (HDL) cholesterol levels after 12-hour fasting between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in LDL Cholesterol Concentration (mg/dL)
Change in serum low-density lipoprotein (LDL) cholesterol levels after 12-hour fasting between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in VLDL Cholesterol Concentration (mg/dL)
Change in serum very low-density lipoprotein (VLDL) cholesterol levels after 12-hour fasting between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in Fasting Insulin Concentration (µIU/mL)
Change in serum fasting insulin levels after 12-hour fasting between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in Serum Zonulin Concentration (ng/mL)
Change in serum zonulin levels assessed by ELISA method between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in Serum Secretory IgA Concentration (mg/dL)
Change in serum secretory IgA levels assessed by ELISA method between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in Serum LPS Concentration (EU/mL)
Change in serum lipopolysaccharide (LPS) levels assessed by ELISA method between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in Gastrointestinal Symptom Rating Scale (GSRS) Total Score (1-7)
Change in total score of the Gastrointestinal Symptom Rating Scale (GSRS) between baseline and 6-month follow-up. The scale consists of 15 items across 5 subscales; scores range from 1 to 7, with higher scores indicating more severe gastrointestinal symptoms.
Time frame: Baseline and 6 months
Change in Body Weight (kg)
Change in body weight between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in Body Mass Index (kg/m²)
Change in BMI between baseline and 6-month follow-up. Weight and height will be combined to report BMI in kg/m².
Time frame: Baseline and 6 months
Change in Waist Circumference (cm)
Change in waist circumference between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in Hip Circumference (cm)
Change in hip circumference between baseline and 6-month follow-up.
Time frame: Baseline and 6 months
Change in Waist-to-Hip Ratio
Change in waist-to-hip ratio between baseline and 6-month follow-up. Waist and hip circumference measurements will be combined to calculate the waist-to-hip ratio.
Time frame: Baseline and 6 months
Change in Daily Energy Intake (kcal/day)
Change in daily energy intake assessed by 3-day dietary intake records between baseline and 6-month follow-up. Data will be analyzed using BeBIS 8.2 software.
Time frame: Baseline and 6 months
Change in Daily Protein Intake (g/day)
Change in daily protein intake assessed by 3-day dietary intake records between baseline and 6-month follow-up. Data will be analyzed using BeBIS 8.2 software.
Time frame: Baseline and 6 months
Change in Daily Carbohydrate Intake (g/day)
Change in daily carbohydrate intake assessed by 3-day dietary intake records between baseline and 6-month follow-up. Data will be analyzed using BeBIS 8.2 software.
Time frame: Baseline and 6 months
Change in Daily Fat Intake (g/day)
Change in daily fat intake assessed by 3-day dietary intake records between baseline and 6-month follow-up. Data will be analyzed using BeBIS 8.2 software.
Time frame: Baseline and 6 months
Plan to share: No — Individual participant data will not be shared due to ethical considerations and participant confidentiality. Data will be stored securely and used only for the purposes of this study in accordance with Turkish Personal Data Protection Law (KVKK) and the ethical approval pending from Toros University Faculty of Health Sciences Non-Interventional Clinical Research Ethics Committee.
Start is estimated for Jul 2026; primary completion for Jan 2027, 6 months later.
Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 6 months is below that.
Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Toros University